REPLIMUNE GROUP INC
NASDAQ: REPL (Replimune Group, Inc.)
Kemas kini terakhir: 7 jam lalu2.87
-0.16 (-5.28%)
| Penutupan Terdahulu | 3.03 |
| Buka | 2.99 |
| Jumlah Dagangan | 7,578,192 |
| Purata Dagangan (3B) | 4,864,950 |
| Modal Pasaran | 236,983,392 |
| Harga / Buku (P/B) | 0.980 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 21 May 2026 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Replimune Group, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -1.00 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fcpm Iii Services B.V. | 31 Dec 2025 | 2,808,368 |
| Erste Asset Management Gmbh | 31 Dec 2025 | 2,120,000 |
| Commodore Capital Lp | 31 Dec 2025 | 1,425,000 |
| Rosalind Advisors, Inc. | 31 Dec 2025 | 1,410,497 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 May 2026 | CNBC | FDA commissioner defends agency's drug approval decisions after wave of backlash |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |